Haemonetics Corporation, a global medical technology company focused on delivering innovative hematology solutions to drive better patient outcomes, has entered into a definitive agreement to sell its wholly-owned subsidiary Inlog Holdings France SAS to Abénex. Abénex is a fully independent private equity firm based in France. Inlog Holdings France SAS, through its subsidiary In Log SAS, develops and sells blood bank and hospital software solutions used predominantly in France and in several other countries outside of the U.S. 
 
"This divestiture and the recent sale of our U.S. blood donor software help shift our portfolio toward our growth segments," said Chris Simon, Haemonetics' president and CEO. "Software that supports our growth and sector leadership remain an important part our Innovation Agenda."
 
Under the terms of the agreement, Haemonetics will transfer all of its ownership interest in Inlog Holdings France SAS and In Log SAS, including the EdgeSuite software solutions, such as EdgeBlood, EdgeCell®, EdgeTrack and EdgeLab, as well as the SapaNet software solution. These products provide a range of solutions to help meet operational needs for blood banks and blood centers and optimize workflow efficiencies in hospital labs to improve patient safety and streamline lab processes. Employees of In Log SAS will remain employees of In Log SAS following the closing of the transaction.
 
"We are enthusiastic about continuing what Haemonetics and the Inlog team have achieved over the last decade. We will rely on Inlog's team to better serve its clients by investing in innovation and in people. We are convinced that Inlog has strong assets to grow within the European market," said Thomas Peretti, Director at Abénex.
 
This transaction is expected to close in the third quarter of calendar 2020, subject to the satisfaction of customary closing conditions.